Biomarkers related with seizure risk in glioma patients: a systematic review

Seizures are common symptoms in patients with glioma and whereas 46% –90% of patients with grade II glioma reportedly experience epileptic seizures before surgery, 42%–71% and 29%–52% of grade III and IV glioma patients, respectively, experience seizures [1–11].Moreover, the incidence of seizures reportedly depends on tumour grade and type [12,13] and increas ed risks of seizure have been observed in patients with gliomas in regions of the temporal lobe [14].Although glioma-related seizures have favourable effects on the overall survival of glioma patients [15–17], undesirable influences on quality of life quality, cognitive dissonance and significant morbidity are inevitable [18],especially long-term epilepsy associated tumor(LEAT) which more commonly encountered in surgical series of patients who have been investigated and treated for drug-resistant seizure episodes for 2 years or longer[19].Thus,better understanding of the pathogenic mechanism s of glioma-related seizures may contribute to seizure control and improve quality of life.
Source: Clinical Neurology and Neurosurgery - Category: Neurosurgery Authors: Source Type: research